We proudly present: Joel Gelfand
Joel M. Gelfand MD MSCE is the James J. Leyden Professor (with tenure) of Dermatology and Epidemiology and Director of the Psoriasis and Phototherapy Treatment Center at the University of Pennsylvania Perelman School of Medicine. He is a nationally and internationally recognized expert in psoriasis, clinical epidemiology, drug safety, and clinical trials. Dr. Gelfand is the recipient of the American Skin Association’s Psoriasis Achievement Award, the Lady Barbara Colyton’s Award for Autoimmune research, the National Psoriasis Foundation’s scientific achievement award, the American Dermatoepidemiology Network’s Founders award, and is an elected member of the American Society for Clinical Investigation. He is an elected member of the Board of Directors for the International Psoriasis Council and the Medical Dermatology Society. Over 30% of dermatologists receiving K23 awards from NIAMS over the last decade have been trainees in the Gelfand lab. His research redefined psoriasis as a systemic inflammatory disease that enhances the risk of cardiovascular events and premature mortality resulting in changes in standard of care guidelines. The overarching goal of his research and clinical practice is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, CV disease and mortality.
Joint Panel Discussion
Prevention of comorbidities: Cardiology and Rheumatology.
